| DC47393 |
PARP/EZH2-IN-1 |
PARP/EZH2-IN-1 is a first-in-class dual PARP (IC50 6.87 nM) and EZH2 (IC50 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA. |
|
| DC47394 |
PARP1-IN-6 |
PARP1-IN-6 is a dual tubulin/PARP-1 inhibitor with IC50 values of 0.94 and 0.48 μM, respectively. |
|
| DC47395 |
CEP-9722 |
CEP-9722, the prodrug of CEP-8983, is a selective and orally active PARP-1 and PARP-2 inhibitor with IC50s of 20 nM and 6 nM, respectively. CEP-9722 has anticancer effects. |
|
| DC47685 |
S-(N-PhenethylthiocarbaMoyl)-L-cysteine |
S-(N-PhenethylthiocarbaMoyl)-L-cysteine, a anticarcinogenic agent, has antileukaemic activity with a GC50 value of 336 nM. S-(N-PhenethylthiocarbaMoyl)-L-cysteine inhibits DNA synthesis in HL60 cells . |
|
| DC47686 |
Thio-ITP |
Thio-ITP (6-Thioinosine 5′-triphosphate) is a RNA polymerase activities competitive inhibitor. |
|
| DC47687 |
DHPS-IN-1 |
DHPS-IN-1, with the best DHPS inhibitory potency (IC50 = 0.014 μM), exhibits excellent inhibition against melanoma cells. |
|
| DC47688 |
Prunasin |
Prunasin is a inhibitor of DNA Polymerase β. |
|
| DC47690 |
Methylnitronitrosoguanidine |
Methylnitronitrosoguanidine (MNNG) is an alkylating agent with toxic and mutagenic effects. |
|
| DC47691 |
Anticancer agent 11 |
Anticancer agent 11 is a broad-spectrum anticancer agent that inhibits angiogenesis and induces DNA cross-links. |
|
| DC47692 |
Colibactin 742 |
Colibactin 742, a stable colibactin derivative, induces DNA interstrand-cross-links, activation of the Fanconi Anemia DNA repair pathway, and G2/M arrest. |
|
| DC47704 |
CDK9-IN-12 |
CDK9-IN-12 displays the optimal CDK9 inhibitory activity with an IC50 value of 5.41 nM. |
|
| DC47705 |
JH-XVI-178 |
JH-XVI-178 is a highly potent and selective inhibitor of CDK8/19 that displays low clearance and moderate oral pharmacokinetic properties. |
|
| DC47706 |
CDK2-IN-7 |
CDK2-IN-7 is a CDK2 inhibitor for treating cancer (IC50 < 50 nM). |
|
| DC47707 |
CDK/HDAC-IN-1 |
CDK/HDAC-IN-1 shows remarkable CDK2/4/6 and HDAC6 inhibitory activity of IC50 = 60.9 ± 2.9, 276 ± 22.3, 27.2 ± 4.2, and 128.6 ± 0.4 nM, respectively. |
|
| DC47897 |
Sovesudil hydrochloride |
Sovesudil (PHP-201) hydrochloride is a potent, ATP-competitive, locally acting Rho kinase (ROCK) inhibitor with IC50s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil hydrochloride lowers intraocular pressure (IOP) without inducing hyperemia. |
|
| DC47898 |
S-MGB-234 |
S-MGB-234 is a minor groove binder of Animal African Trypanosomiasis (AAT). S-MGB-234 displays excellent in vitro activities against the principal causative organisms of AAT; Trypanosoma congolense, and Trypanosoma vivax. S-MGB-234 does not show cross-resistance with the current diamidine drugs and are not internalized via the transporters used by diamidines. |
|
| DC47914 |
Ribociclib-d6 hydrochloride |
Ribociclib D6 (LEE011 D6) hydrochloride is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex. |
|
| DC47924 |
PERK-IN-4 |
PERK-IN-4 is a potent and selective PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase) inhibitor with an IC 50 of 0.3 nM. PERK is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states. |
|
| DC47956 |
Lurbinectedin-d3 |
Lurbinectedin D3 is deuterium labeled Lurbinectedin. Lurbinectedin (PM01183) is a DNA minor groove covalent binder with potent anti-tumour activity; inhibits RMG1 and RMG2 cell growth with IC50 values of 1.25 and 1.16 nM, respectively. |
|
| DC47966 |
KH-CB20 |
KH-CB20, an E/Z mixture, is a potent and selective inhibitor of CLK1, with an IC50 of 16.5 nM. KH-CB20 also can inhibits DYRK1A (IC50=57.8 nM) and CLK3 (IC50=488 nM). |
|
| DC47986 |
Gemcitabine elaidate hydrochloride |
Gemcitabine elaidate (CP-4126) hydrochloride is lipophilic pro-drug of Gemcitabine. Gemcitabine elaidate hydrochloride is converted to Gemcitabine by esterases in order to be phosphorylated. Gemcitabine elaidate hydrochloride exhibits anti-tumor activity. |
|
| DC47992 |
Flurocitabine |
Flurocitabine is a fluorinated anlydride analog of cytosine arabinoside, partially hydrolysecl in vivo into two active antitumor substances (arabinosyl-tluorocytosine (ara-FC) and arabinosyl-fluorouracil (ara-FU)). Flurocitabine has antitumor activity during phase I studies in acute leukemia and solid tumors. |
|
| DC47998 |
Elomotecan hydrochloride |
Elomotecan (hydrochloride) is a potent inhibitor of topoisomerases I and II. Elomotecan (hydrochloride) is a camptothecin analog belonging to the homocamptothecin family (hCPT). Elomotecan (hydrochloride) reduces the proliferation of different tumor cells with higher potency than other anticancer drugs of reference targeting topoisomerases I or II. |
|
| DC47999 |
D-Xylofuranose, 1,2,3,5-tetraacetate |
D-Xylofuranose, 1,2,3,5-tetraacetate is the raw material for nucleotides synthesis. |
|
| DC48000 |
Dxd-d5 |
Dxd-D5 (Exatecan-D5 derivative for ADC) is a deuterium labeled Dxd. Dxd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) . |
|
| DC48001 |
DS96432529 |
DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition. |
|
| DC48007 |
Diflomotecan |
Diflomotecan (BN 80915) is a potent inhibitor of topoisomerase I. Diflomotecan causes enhanced plasma stability and has the superior preclinical anti-tumour activity compared with other established compounds. |
|
| DC48018 |
CP-67015 |
CP-67015, a nalidixic acid analog, is a potent topoisomerase II inhibitor. CP-67015 is a positive direct-acting mutagen in mammalian cells with both gene and chromosomal level effects. |
|
| DC48027 |
CDK7-IN-7 |
CDK7-IN-7 is a potent and selective CDK7 kinase inhibitor with an IC50 of <50 nM (Patent CN112661745A, compound T-01). |
|
| DC48028 |
CDK7-IN-6 |
CDK7-IN-6 is a potent and selective cyclin-dependent kinase (CDK7) inhibitor (IC50≤100 nM), extracted from patent WO2019197549 A1, compound 210. CDK7-IN-6 is > 200-fold selective for CDK7 over CDK1, CDK2, and CDK5. CDK7-IN-6 can be used for the research of cancer. |
|
